Cytek Biosciences Inc. Common Stock Q2 2026 Earnings Recap

CTKB Q2 2026 August 7, 2026

Get alerts when CTKB reports next quarter

Shares declined 2.8% after the Q2 report, reflecting investor caution despite steady revenue growth, with margin pressures and weakness in EMEA likely weighing on sentiment.

Earnings Per Share Beat

$-0.05 vs $-0.09 est.

+46.4% surprise

Revenue Beat

48140000 vs 47309700 est.

+1.8% surprise

Market Reaction

1-Day +0.0%

5-Day +13.81%

See CTKB alongside your other holdings

Add to your portfolio — free

Key Takeaways

Q2 revenue grew 6% year-over-year to $48.1 million, driven by double-digit growth in U.S. and China markets.
U.S. revenue increased 18% to $28.2 million, supported by gains in academic and government sectors and service business.
EMEA revenue declined approximately 8% year-over-year, impacted by ongoing regional budgetary constraints.
Total APAC revenue was flat, with strong growth in China offset by softness elsewhere in the region.
Recurring revenue from reagents and services rose 8% to $18.5 million, now 35% of trailing twelve-month revenue, up from 32% a year ago.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit CTKB on AllInvestView.

Previous Q1 2026